SCHEMBL20818003

SCHEMBL20818003

Cc1cn(Cc2ccccc2C(F)(F)F)c(=O)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
ATM Q13315 3/20 0.44
GAA P10253 2/20 0.44
KMT2A Q03164 2/20 0.40
CHRM5 P08912 1/20 0.40
MAPK1 P28482 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
MEN1 O00255 1/20 0.39
COMT P21964 1/20 0.39
P2RX7 Q99572 3/20 0.39
C5AR1 P21730 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818041 0.78 MKNK1 (0.41) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL20817931 0.77 TDP1 (0.44) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL20817784 0.74 MKNK1 (0.54) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL1642057 0.71 HSP90AA1 (0.49) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL15816769 0.67 BRD4 (0.67) MKNK1MKNK2TDP1
SCHEMBL20818715 0.67 CA12 (0.39) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL76388 0.67 C5AR1 (0.50) ALDH1A1KDM4EC5AR1
SCHEMBL31333054 0.67 ALDH1A1 (0.47) MKNK1MKNK2ALDH1A1KDM4ETDP1
SCHEMBL2175162 0.66 MAPK14 (0.43) ALDH1A1TDP1MAPK1
SCHEMBL25431886 0.65 NPBWR1 (0.42) ALDH1A1KDM4ETDP1NPSR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN MKNK1 1944/4885MKNK2 1263/4885ALDH1A1 649/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN MKNK1 1944/4885MKNK2 1263/4885ALDH1A1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.